NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated patients frequently experience debilitating side effects, and many patients delay the start of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and hematologic toxicity. To date, most of the evidence underlying the current treatment recommendations has come from observational studies in which either a macrolide has been combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The proposed study will answer whether a third drug is necessary or whether taking two drugs can increase tolerability without a substantial loss of efficacy.
Conditions
- Mycobacterium Avium Complex
- Nontuberculous Mycobacterium Infection
Intervention
- Azithromycin
- Ethambutol
- Rifampin
Principal Investigator
- Moretta, Dafne
Sponsor
- Patient-Centered Outcomes Research Institute
*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 12/22/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.
Request Information
Complete the form below to contact the study team and receive more information about this trial.